ABCELLERA BIOLOGICS INC (ABCL) Stock Price, Forecast & Analysis
USA - NASDAQ:ABCL - CA00288U1066 - Common Stock
ABCL Key Statistics, Chart & Performance
The current stock price of ABCL is 5.55 USD. In the past month the price decreased by -5.93%. In the past year, price increased by 103.3%.
ABCL Latest News, Press Relases and Analysis
ABCL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.33 | 214.25B | ||
| DHR | DANAHER CORP | 27.94 | 154.22B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.09 | 47.98B | ||
| A | AGILENT TECHNOLOGIES INC | 26.86 | 41.49B | ||
| IQV | IQVIA HOLDINGS INC | 18.61 | 36.80B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.63 | 29.18B | ||
| WAT | WATERS CORP | 28.59 | 20.81B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.9 | 20.28B | ||
| ILMN | ILLUMINA INC | 28.33 | 18.99B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.9 | 16.43B | ||
| TEM | TEMPUS AI INC | N/A | 15.61B | ||
| ICLR | ICON PLC | 13.03 | 13.36B |
Related stock screener links
About ABCL
Company Profile
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Company Info
ABCELLERA BIOLOGICS INC
150 W 4Th Avenue
Vancouver BRITISH COLUMBIA CA
Employees: 596
Phone: 16045599005
ABCELLERA BIOLOGICS INC / ABCL FAQ
What does ABCELLERA BIOLOGICS INC do?
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
What is the stock price of ABCELLERA BIOLOGICS INC today?
The current stock price of ABCL is 5.55 USD. The price increased by 3.54% in the last trading session.
What is the dividend status of ABCELLERA BIOLOGICS INC?
ABCL does not pay a dividend.
What is the ChartMill rating of ABCELLERA BIOLOGICS INC stock?
ABCL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ABCELLERA BIOLOGICS INC (ABCL) stock traded?
ABCL stock is listed on the Nasdaq exchange.
What do analysts say about ABCELLERA BIOLOGICS INC (ABCL) stock?
14 analysts have analysed ABCL and the average price target is 9.47 USD. This implies a price increase of 70.66% is expected in the next year compared to the current price of 5.55.
What is the GICS sector and industry of ABCL stock?
ABCELLERA BIOLOGICS INC (ABCL) operates in the Health Care sector and the Life Sciences Tools & Services industry.
ABCL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ABCL. When comparing the yearly performance of all stocks, ABCL is one of the better performing stocks in the market, outperforming 93.54% of all stocks.
ABCL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABCL. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability.
ABCL Financial Highlights
Over the last trailing twelve months ABCL reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -1.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.82% | ||
| ROE | -16.45% | ||
| Debt/Equity | 0 |
ABCL Forecast & Estimates
14 analysts have analysed ABCL and the average price target is 9.47 USD. This implies a price increase of 70.66% is expected in the next year compared to the current price of 5.55.
For the next year, analysts expect an EPS growth of -13.13% and a revenue growth 4.72% for ABCL